Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Douglas A. McIntyre | Sep 11, 2007 at 4:56 AM EDT

A Black Eye For Biofuels

All those "green" people out there may want to take into consideration the fact that biofuels are unlikely to have…

Douglas A. McIntyre | Sep 10, 2007 at 4:24 PM EDT

Bayer’s Death Drug

Add to the list of reasons not to have open heart surgery the potential use of Bayer’s (BAY) Trasylol to…

Douglas A. McIntyre | Sep 10, 2007 at 11:49 AM EDT

A True Believer Walks Out On Cardica

Medical device market Cardica (CRDC) hit a all-time high last Wednesday as a group of surgeons "successfully used its automated…

Douglas A. McIntyre | Sep 9, 2007 at 4:29 PM EDT

The Trouble Will Not End For Boston Scientific

Boston Scientific (BSX) has been vexed by problems with its stents, one of its largest businesses. There have been several…

Douglas A. McIntyre | Sep 7, 2007 at 8:45 AM EDT

Hollis-Eden Jumps 30%

Hollis-Edent (HEPH) is a very small development-stage pharmaceutical company. It has no revenue as has lost about $7 million each…

Douglas A. McIntyre | Sep 6, 2007 at 4:59 PM EDT

‘If, Then’…. Amgen Could Recover Much More (AMGN, BIIB)

Amgen (NASDAQ:AMGN) has seen a slight recovery of late, mostly on reports that the U.S. Senate is asking Centers for…

Douglas A. McIntyre | Sep 6, 2007 at 1:47 PM EDT

Bioheart Sets IPO Terms (BHRT)

Bioheart Inc. has set its IPO terms and it will trade under the NASDAQ ticker "BHRT." BioHeart has set its…

Douglas A. McIntyre | Sep 5, 2007 at 8:41 AM EDT

AtheroGenics Gets Knocked Down

Drug developer AtheroGenics (AGIX) said Wednesday its failed heart-drug candidate showed signs it may be effective as an oral anti-diabetic…

Douglas A. McIntyre | Sep 5, 2007 at 5:00 AM EDT

Pfizer: Stay On That Lipitor

Patients who swtich from Pfizer’s (PFE) monster selling drug cholesterol pill Lipitor to Merck’s (MRK) Zocor, now available in generic…

Douglas A. McIntyre | Sep 4, 2007 at 6:59 PM EDT

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that "patients given…

Douglas A. McIntyre | Sep 3, 2007 at 7:56 AM EDT

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

http://www.bloomberg.com/apps/news?pid=20601087&sid=ajZ2lVrqeb2I&refer=homeA study out fo Sweden may help the flagging fortunes of the stent businesses at Boston Scientific (BSX) and Johnsohn…

Douglas A. McIntyre | Sep 1, 2007 at 3:18 PM EDT

Gene Logic: A Discount Value Pick, Or A Major Value Trap? (GLGC)

Genel Logic (NASDAQ:GLGC) is a stock that is either one incredible value stock in biotech land, or it is just…

Douglas A. McIntyre | Aug 31, 2007 at 12:05 PM EDT

IPO FILING: ARYx Therapeutics, Inc. (ARYX, PG)

ARYx THERAPEUTICS, INC. has filed to raise up to $86.25 million in an IPO under the ticker "ARYX" on NASDAQ. …

Douglas A. McIntyre | Aug 31, 2007 at 4:50 AM EDT

The Ariad Pharmaceuticals Conundrum (ARIA, MRK)

Business Week has run a brief feature article on Ariad Pharmaceuticals (NASDAQ:ARIA) in its "Inside Wall Street" magazine section and…

Douglas A. McIntyre | Aug 28, 2007 at 8:38 AM EDT

Xoma Gets A Boost

Biopharmaceutical company Xoma (XOMA) is having its luck day. After its stock traded down as low as $2.24, its shares…

1 … 365 366 367 368 369 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

A Black Eye For Biofuels

Bayer’s Death Drug

A True Believer Walks Out On Cardica

The Trouble Will Not End For Boston Scientific

Hollis-Eden Jumps 30%

‘If, Then’…. Amgen Could Recover Much More (AMGN, BIIB)

Bioheart Sets IPO Terms (BHRT)

AtheroGenics Gets Knocked Down

Pfizer: Stay On That Lipitor

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

Gene Logic: A Discount Value Pick, Or A Major Value Trap? (GLGC)

IPO FILING: ARYx Therapeutics, Inc. (ARYX, PG)

The Ariad Pharmaceuticals Conundrum (ARIA, MRK)

Xoma Gets A Boost

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Forget Intel Corporation: As June Volatility Rocks Chip Stocks, This Tech Monopoly Is The Smart Money Pivot

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

Can You Afford To Retire To Trump Tower? We Ran the Budget. It's a Lot.

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Health and Healthcare Articles

All Health and Healthcare Articles

A Black Eye For Biofuels

Bayer’s Death Drug

A True Believer Walks Out On Cardica

The Trouble Will Not End For Boston Scientific

Hollis-Eden Jumps 30%

‘If, Then’…. Amgen Could Recover Much More (AMGN, BIIB)

Bioheart Sets IPO Terms (BHRT)

AtheroGenics Gets Knocked Down

Pfizer: Stay On That Lipitor

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

Gene Logic: A Discount Value Pick, Or A Major Value Trap? (GLGC)

IPO FILING: ARYx Therapeutics, Inc. (ARYX, PG)

The Ariad Pharmaceuticals Conundrum (ARIA, MRK)

Xoma Gets A Boost

Stock Market Live June 10, 2026: S&P 500 (SPY) Sinks on Fear of War

Live Nasdaq Composite: Market Rout Deepens as Inflation Hits Three-Year High and Oil Climbs

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

May CPI Surges to 4.2%, but the Fed May Not Be Ready to Raise Rates

Forget Intel Corporation: As June Volatility Rocks Chip Stocks, This Tech Monopoly Is The Smart Money Pivot

Featured Reads

A 73 Year Old With $1.6 Million in a Traditional 401(k) Faces a $60,400 First RMD That Quietly Triggers an IRMAA Surcharge

Can You Afford To Retire To Trump Tower? We Ran the Budget. It's a Lot.